Working… Menu

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02481154
Recruitment Status : Active, not recruiting
First Posted : June 25, 2015
Last Update Posted : August 24, 2021
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.